UK’s Breast Cancer therapeutics market size stood at around USD XX.X billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 8.6% during the forecast period.
Increasing the incidence of breast cancer coupled with a growing awareness program towards breast cancer diagnosis and treatment are the major factors that contributing to the growth of the market. The awareness programs and research funding on breast cancer also enable in the growth of the market. In 2015 the Public Health England (PHE) launched the ‘Be Clear on Cancer’ campaign for the purpose of women aged 70 and over to drive awareness of the risk of breast cancer. Cancer Research UK funded about $38 million for breast cancer research in 2017. This funding enabled to create a network of research at 90 institutions in more than 40 states in the UK. The National Institute for Health and Care Excellence (NICE) set the quality standard for breast cancer that covers the care of people with breast cancer after being referred to a specialist team.
Market Driving and Restraining Factors
The driving factors for the growth of the Breast Cancer therapeutics market in UK includes:
- Rising prevalence of Breast cancer
- Growing healthcare spending for cancer
- Launch of technologically advanced therapeutics
One of the foremost drivers influencing the growth of the market is the increased prevalence of breast cancer, which is expected to result in a large patient population demanding accurate and efficient treatment options. Furthermore, the increasing demand for preventive care and early treatment has led many individuals to undergo cancer screening tests, which would also strongly drive the number of patients demanding treatment in the forecast period. As the number of patients suffering from breast cancer continues to increase, the importance and the critical need for the development of advanced therapeutics for better outcomes remains unparalleled.
- Adverse effects of therapeutics
Adverse reactions arising from breast cancer therapeutics, such as targeted therapies, may limit the market growth soon. In cases of severe adverse reactions, the patient may not be able to use that drug and may have to move toward other types of therapeutics.
Breast Cancer Stages
The stage of a breast cancer is determined by the cancer’s characteristics, such as how large it is and whether it has hormone receptors. These stages are classified as:
- Stage 0
- Stage I
- Stage 2
- Stage 3
- Stage 4
Incidence rates in the observation period increased, as they were affected by the increasing number of cases with early-stage cancers being diagnosed in the screening age group. The total incidence of early-stage cancer, which included the incidence of non-invasive breast cancers, increased by 14.5% between 2005 and 2016.
Advanced stage breast cancer rates (UICC II+) started to decline during fully implemented screening program. Advanced stage breast cancer declines were not observed in women newly eligible for screening
Early-stage cancers (UICC stages 0 and I) increased by 48.1% while late-stage diagnoses (UICC stages III and IV) decreased by 31.6%.
These changes can be attributed to developing infrastructure and expertise in breast cancer market.